MedTrace Logo

Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10

NCT04912297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2021-08-11

Study results available
· View outcomes & findings →

Summary

The aim of the study are to assess the persistence of immunity against vaccine serotypes (VSTs) and vaccine-related serotypes in PCV10 vaccinated children in Finland.

Conditions

  • Pneumococcal Infections

Interventions

BIOLOGICAL

10-valent pneumococcal conjugate vaccine, PCV10

10-valent pneumococcal conjugate vaccine, PCV10

Sponsors & Collaborators

  • Turku University Hospital

    collaborator OTHER_GOV

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Finnish Institute for Health and Welfare

    lead OTHER_GOV

Principal Investigators

  • Arto Palmu, MD, PhD · Finnish Institute for Health and Welfare

Eligibility

Min Age
13 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-12
Primary Completion
2013-05-07
Completion
2013-05-07
FDA Drug
Yes

Countries

  • Finland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912297 on ClinicalTrials.gov